NASDAQ:GH - Guardant Health Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $168.75
  • Forecasted Upside: 32.21 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
▲ +4.22 (3.42%)

This chart shows the closing price for GH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Guardant Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GH

Analyst Price Target is $168.75
▲ +32.21% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Guardant Health in the last 3 months. The average price target is $168.75, with a high forecast of $195.00 and a low forecast of $135.00. The average price target represents a 32.21% upside from the last price of $127.64.

This chart shows the closing price for GH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 12 contributing investment analysts is to buy stock in Guardant Health. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/21/2021Wells Fargo & CompanyBoost Price TargetOverweight$145.00 ➝ $160.00Low
6/15/2021Raymond JamesInitiated CoverageMarket PerformHigh
6/3/2021The Goldman Sachs GroupInitiated CoverageBuy$160.00Low
5/27/2021William BlairReiterated RatingBuyLow
5/25/2021Wells Fargo & CompanyInitiated CoverageOverweight$145.00Low
5/23/2021SVB LeerinkReiterated RatingBuyLow
5/7/2021BTIG ResearchBoost Price TargetBuy$145.00 ➝ $160.00Medium
5/7/2021Morgan StanleyLower Price TargetOverweight$175.00 ➝ $160.00High
2/26/2021Morgan StanleyBoost Price TargetOverweight$130.00 ➝ $175.00Medium
2/25/2021CitigroupBoost Price TargetBuy$155.00 ➝ $190.00High
2/25/2021CowenBoost Price TargetOutperform$140.00 ➝ $190.00High
2/25/2021Canaccord GenuityReiterated RatingBuy$195.00High
1/20/2021SVB LeerinkBoost Price TargetOutperform$150.00 ➝ $190.00Medium
1/12/2021Canaccord GenuityBoost Price Target$145.00 ➝ $170.00Medium
1/11/2021Stifel NicolausInitiated CoverageBuy$175.00High
12/17/2020BTIG ResearchBoost Price TargetBuy$132.00 ➝ $145.00High
12/16/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target$145.00 ➝ $155.00Low
12/16/2020Smith Barney CitigroupBoost Price Target$145.00 ➝ $155.00Low
12/11/2020SVB LeerinkBoost Price TargetOutperform$130.00 ➝ $150.00High
11/12/2020William BlairReiterated RatingOutperformLow
11/9/2020Morgan StanleyBoost Price TargetOverweight$110.00 ➝ $130.00Medium
11/6/2020JPMorgan Chase & Co.Boost Price TargetOverweight$120.00 ➝ $135.00Medium
9/9/2020Morgan StanleyInitiated CoverageOverweight$110.00High
6/11/2020BTIG ResearchInitiated CoverageBuy$100.00Low
5/8/2020SVB LeerinkReiterated RatingBuy$125.00 ➝ $130.00High
5/8/2020Canaccord GenuityReiterated RatingBuy$125.00High
5/8/2020CitigroupBoost Price TargetBuy$100.00 ➝ $110.00High
4/23/2020SVB LeerinkLower Price TargetOutperform$130.00 ➝ $125.00Medium
2/25/2020Canaccord GenuityReiterated RatingBuy$125.00High
2/21/2020GuggenheimInitiated CoverageBuy$103.00Medium
1/6/2020CitigroupInitiated CoverageBuy$100.00High
11/8/2019William BlairReiterated RatingOutperformLow
11/8/2019Canaccord GenuityReiterated RatingBuy$125.00High
10/24/2019Canaccord GenuityReiterated RatingBuy$125.00Medium
8/7/2019CowenSet Price TargetBuy$110.00High
8/7/2019Canaccord GenuityReiterated RatingBuy ➝ Buy$96.00 ➝ $125.00High
8/7/2019JPMorgan Chase & Co.Boost Price TargetOverweight$90.00 ➝ $135.00High
5/10/2019JPMorgan Chase & Co.Boost Price TargetOverweight$85.00 ➝ $90.00High
4/16/2019Canaccord GenuityInitiated CoverageBuy ➝ Buy$90.00Low
4/10/2019Bank of AmericaUpgradeNeutral ➝ Buy$84.00High
4/3/2019CowenBoost Price TargetOutperform$40.00 ➝ $70.00Low
3/13/2019William BlairReiterated RatingOutperformHigh
3/13/2019JPMorgan Chase & Co.Boost Price TargetOverweight$42.00 ➝ $85.00High
2/28/2019Bank of AmericaReiterated RatingNeutral ➝ Neutral$42.00 ➝ $60.00High
10/29/2018SVB LeerinkReiterated RatingOutperformMedium
10/29/2018CowenInitiated CoverageOutperformHigh
10/29/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$42.00High
10/29/2018William BlairInitiated CoverageOutperform ➝ OutperformHigh
10/29/2018Bank of AmericaInitiated CoverageNeutral ➝ Neutral$37.00High
(Data available from 6/23/2016 forward)
Guardant Health logo
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $127.64
Low: $122.69
High: $129.68

50 Day Range

MA: $131.58
Low: $109.77
High: $165.68

52 Week Range

Now: $127.64
Low: $77.50
High: $181.07


1,767,384 shs

Average Volume

1,029,584 shs

Market Capitalization

$12.91 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Guardant Health?

The following Wall Street analysts have issued stock ratings on Guardant Health in the last year: BTIG Research, Canaccord Genuity, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, JPMorgan Chase & Co., Morgan Stanley, Raymond James, Smith Barney Citigroup, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., Wells Fargo & Company, William Blair, and Zacks Investment Research.
View the latest analyst ratings for GH.

What is the current price target for Guardant Health?

12 Wall Street analysts have set twelve-month price targets for Guardant Health in the last year. Their average twelve-month price target is $168.75, suggesting a possible upside of 32.2%. Canaccord Genuity has the highest price target set, predicting GH will reach $195.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $135.00 for Guardant Health in the next year.
View the latest price targets for GH.

What is the current consensus analyst rating for Guardant Health?

Guardant Health currently has 1 hold rating and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GH will outperform the market and that investors should add to their positions of Guardant Health.
View the latest ratings for GH.

What other companies compete with Guardant Health?

How do I contact Guardant Health's investor relations team?

Guardant Health's physical mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The company's listed phone number is 855-698-8887 and its investor relations email address is [email protected] The official website for Guardant Health is